Navigation Links
Omeros Files Orphan Drug Application for Treatment of Atypical Hemolytic Uremic Syndrome with OMS721
Date:4/17/2013

SEATTLE, April 17, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has filed an Application for Orphan Drug Designation with the U.S. Food and Drug Administration (FDA) for OMS721, the lead human monoclonal antibody in Omeros' mannan-binding lectin-associated serine protease-2 (MASP‑2) program, for use in the treatment of atypical hemolytic uremic syndrome (aHUS). As Omeros previously announced, based on positive preclinical data in thrombotic microangiopathy (TMA), the first indication planned for OMS721 clinical trials is aHUS, a rare but life-threatening form of TMA. Orphan drug designation is granted to treatments that are expected to provide significant therapeutic advantage over existing treatments and that target conditions affecting 200,000 or fewer U.S. patients per year. Orphan-designated drugs are eligible for incentives such as a faster approval process and additional market exclusivity.

Omeros controls the worldwide rights to MASP-2 and all therapeutics targeting MASP-2, a novel pro-inflammatory protein involved in activation of the complement system – an important component of the immune system. The complement system plays a role in the inflammatory response to tissue damage or microbial infection. OMS721 selectively inhibits MASP-2, blocking the lectin pathway of the complement system while leaving intact the classical pathway, which represents the acquired immune response to infection. Soliris® (eculizumab), which received orphan drug status for aHUS and is the only currently approved therapy for that indication, inhibits microbial killing by the classical pathway, increasing the risk of infection for the patient. By targeting only the lectin pathway and leaving the classical pathway intact, OMS721 should not have this increased infection risk. In addition, Soliris requires a
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros Announces that GPR17 Antagonists Improve Function in Model of Multiple Sclerosis
2. Omeros Announces Positive OMS721 Data in Model of Thrombotic Microangiopathy
3. Omeros to Present at the 2013 Future Leaders in the Biotech Industry Conference
4. Omeros Announces Toxicology Data that Support Advancing MASP-2 Inhibitor into Clinical Trials
5. Omeros Announces Successful Completion of PDE10 Phase 1 Multiple Ascending Dose Trial
6. Omeros Elucidates Mechanism of its PDE7 Inhibitors in Addiction
7. Omeros to Present at the Cowen and Company 33rd Annual Health Care Conference
8. Omeros Announces Toxicology Study Data from MASP-2 Inhibitor
9. Omeros Announces Positive OMS302 Safety Data in Phase 3 Clinical Trial
10. Omeros Announces Encouraging Data from Phase 1 Clinical Trial for PDE10 Program
11. Omeros to Present at the 24th Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , November 26, 2014 Investor-Edge ... VVUS ), Horizon Pharma PLC (NASDAQ: ... and Johnson (NYSE: JNJ ), and Theravance Inc. ... companies can be accessed at: http://investor-edge.com/register . ... 4,758.25, up 0.07%, the Dow Jones Industrial Average edged 0.02% ...
(Date:11/26/2014)... 26, 2014 A hernia is condition ... protrudes through the wall of a weak muscle area. Obesity, ... are some of the causes of hernias. There are several ... incisional. An inguinal hernia is when part of the abdominal ... found in the area of the umbilicus. A hiatal hernia ...
(Date:11/26/2014)... 2014  Aridis Pharmaceuticals, Inc., a biopharmaceutical company ... infectious diseases, announced today the addition of ... opinion leader in the areas of pneumonia and ... Founder and Chief Executive Officer, Vu ... extensive experience investigating bacterial toxins and key mechanisms ...
Breaking Medicine Technology:Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5Global Hernia Repair Devices Market Size, Share, Trends and Forecast 2014 to 2018 - Big Market Research 2Global Hernia Repair Devices Market Size, Share, Trends and Forecast 2014 to 2018 - Big Market Research 3Global Hernia Repair Devices Market Size, Share, Trends and Forecast 2014 to 2018 - Big Market Research 4Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 3
... NovaRx Corporation announced today the appointment of Norrie ... Chief Operating Officer. Dr. Russell brings to the ... and a long history of success driving innovation in ... leading entrepreneurial biotechnology companies developing pioneering new technologies. ...
... 3 Sangamo BioSciences, Inc.,(Nasdaq: SGMO ) ... milestones,achieved in 2008 and preview objectives for 2009 during ... New York City today. , David Smoller, ... discuss the progress and expected potential of the,two companies, ...
Cached Medicine Technology:NovaRx Appoints Industry Veteran as President and COO 2NovaRx Appoints Industry Veteran as President and COO 3Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 2Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 3Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 4Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 5Sangamo BioSciences Provides Update on Company's 2008 Progress and 2009 Objectives 6
(Date:11/27/2014)... HealthDay Reporter , WEDNESDAY, Nov. 26, ... acquire a second language, new research suggests. But anyone who ... a brain boost, the small study finds. The ... co-author Ping Li, co-director of the Center for Brain, Behavior ... interesting, Li said, that "the brain networks of the more ...
(Date:11/27/2014)... (PRWEB) November 27, 2014 In order to ... from Sharpes, Fla., designed an easy way to avoid touching ... , He then created a prototype of the patent-pending Toilet ... lower a toilet seat and/or lid in a more sanitary ... the spread of germs. Overall, it promotes good hygiene and ...
(Date:11/27/2014)... York, New York (PRWEB) November 27, 2014 ... of individuals who were allegedly injured by the medication ... where a federal litigation is looking ahead to a ... , According to a Scheduling Order issued earlier this ... place on December 16th at 10:00 a.m. Items likely ...
(Date:11/27/2014)... “LAB.C” was featured on NewsWatch as part of its monthly ... available to consumers. Mallory Sofastaii, a technology expert and reporter ... with viewers the company offers a cable case, iBed, and ... portability and functionality. A unique mobile company at IFA ... 5S has a portable USB charger built in. The certified ...
(Date:11/27/2014)... Burnsville MN (PRWEB) November 27, 2014 ... manufacturer of office ergonomics equipment , has announced ... partnership with Commercial Office Environments. The partnership will ... for office furnishings location. , In addition to ... the new dealer partnership promotes HealthPostures' products with ...
Breaking Medicine News(10 mins):Health News:Some People May Be Pre-Wired to Be Bilingual 2Health News:Some People May Be Pre-Wired to Be Bilingual 3Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 3Health News:Top Mobile Friendly Accessories were Featured on NewsWatch Television on October 30, 2014 2Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2
... of compounds commonly found in garlic may not only ... they inhibit the infection appears to be similar to ... from the University of Toronto report these findings at ... Tropical Medicine and Hygiene in Atlanta.// ,The compounds ...
... to suffer brain cell damage from long-term use of the ... if they stop taking the drug. Studies have shown that ... damage nerve endings that release serotonin, a brain chemical that ... to damage brain cells that transmit nerve signals. // ...
... drug simvastatin with the B vitamin niacin lowers the ... up to 90% in some patients. The study of ... (good) cholesterol showed that 3 years of the combo ... and significantly lowered heart complications compared with an inactive ...
... of “lefties” tend to make a person better at ... in the affirmative. This recent reasearch is reported in the ... of the University of Toledo in Ohio, studied memory ... don’t have to be personally left-handed to share a ...
... by the hypothalamus, the area of the brain that ... may underlie chronic migraines. The findings provide hope for ... suffer from the debilitating headaches, since drugs that regulate ... the headaches, according to Dr. Mario Peres, the study's ...
... do not realise that future patients are more likely to ... - or any other disease - unless there are clinical ... in California gathered views from more than 200 patients involved ... 60 per cent realised they might not get any direct ...
Cached Medicine News:Health News:Simvastatin Plus Niacin May Lower Heart Risks 2
Wright-Giemsa Stain Solutions...
... For fast, single-solution staining, Hema-Quik ... slides into stain solution for ... to deionized water for five ... second time by dipping quickly ...
... for staining of peripheral blood smears ... stain formulations still in use today. ... of Giemsa stain, although eosinophillic granules ... granules and nuclear chromatin stain a ...
This stain is the McNeal formula and can be substituted for Wright Stain solution....
Medicine Products: